Can women take finasteride for hair loss?

Finasteride is not FDA-approved for hair loss in women and is contraindicated in women who are pregnant or may become pregnant. Some dermatologists use it off-label in postmenopausal women only, with limited evidence. Women of childbearing potential should not take it.

Why is finasteride dangerous for pregnant women?

Finasteride inhibits Type II 5-alpha reductase, which is needed for normal male fetal development. If taken during pregnancy, it can cause abnormalities of the external genitalia in a male fetus. Even handling crushed tablets can be a risk for pregnant women.

Does finasteride work for female pattern hair loss?

The evidence is weak and mixed. A large RCT in postmenopausal women found no significant benefit vs placebo. Female pattern hair loss has a different hormonal profile than male pattern hair loss, and DHT reduction appears less central to its pathology.

What is the best treatment for women with hair loss?

Topical minoxidil 2% (twice daily) and 5% foam (once daily) are the only FDA-approved drug treatments for female pattern hair loss. Oral minoxidil is used off-label. Spironolactone is used off-label for women with androgenic alopecia. A dermatologist can advise based on individual assessment.

Can postmenopausal women use finasteride?

Some dermatologists prescribe finasteride off-label in postmenopausal women who have not responded to other treatments. The evidence is limited and inconsistent. It is not a standard-of-care recommendation and is not FDA-approved for this use.

Is spironolactone safer than finasteride for women?

Spironolactone is commonly used off-label for women with hair loss related to androgens and has a better-established evidence base in women than finasteride. It is not FDA-approved for hair loss but is a well-known drug with decades of clinical use for other conditions. A dermatologist can advise on the relative merits for individual cases.

Finasteride for Women: Safety and Evidence

Last updated: Apr 20, 2026Fact CheckOral FinasterideBased on 1 study

This is a research-based fact check, not medical advice. The findings summarized here come from peer-reviewed studies and are presented without added opinions. Consult a certified healthcare practitioner before making any treatment decision.

Verdict

Finasteride is not FDA-approved for women with hair loss and is contraindicated in women who are pregnant or may become pregnant. Women of childbearing potential should not take it. Some dermatologists use finasteride off-label in postmenopausal women only, with limited evidence support. Topical minoxidil is the FDA-approved first-line treatment for women with female pattern hair loss. The evidence base for finasteride in women is substantially weaker than for men.

Key takeaways

Finasteride is NOT FDA-approved for hair loss in women.
It is contraindicated in women of childbearing potential due to teratogenic risk (Category X in pregnancy).
Women must not handle crushed or broken tablets if pregnant or potentially pregnant.
Off-label use is limited to postmenopausal women only, with limited clinical evidence.
Topical minoxidil is the FDA-approved first-line treatment for women with female pattern hair loss.
Other off-label options for women with female pattern hair loss include spironolactone and oral minoxidil.

Finasteride is contraindicated in women who are pregnant or may become pregnant. It can cause abnormalities of the external genitalia of a male fetus (ambiguous genitalia) due to inhibition of Type II 5-alpha reductase. Women who are pregnant or may become pregnant must not handle crushed or broken finasteride tablets. Finasteride is not FDA-approved for hair loss in women.

Regulatory status and contraindication

Finasteride was approved by the FDA for male pattern hair loss and for benign prostatic hyperplasia. It is explicitly not indicated in women. The FDA label states that finasteride is contraindicated in women when they are or may potentially be pregnant, due to the ability of 5-alpha reductase inhibitors to inhibit the conversion of testosterone to DHT, which is essential for the normal development of male external genitalia in a fetus. Women who are pregnant or may become pregnant should not handle crushed or broken tablets. An overview of evidence-based treatment options for women with hair loss is in the hair restoration guide.

Evidence for postmenopausal women

A small number of clinical studies have examined finasteride in postmenopausal women with female pattern hair loss. Results have been mixed. One large randomised controlled trial found no significant difference between finasteride 1mg and placebo in postmenopausal women. Some smaller studies and case series have shown modest benefit. The evidence base is substantially weaker than for men, and no consistent efficacy signal has emerged from controlled trials in women.

Where off-label use occurs in clinical practice, it is limited strictly to postmenopausal women (no childbearing potential) who have not responded adequately to topical minoxidil. This is not a standard-of-care recommendation and represents specialist practice.

Why finasteride is less likely to work in women

Female pattern hair loss (FPHL) has a different hormonal profile than male pattern hair loss. While androgens may play a role in some women, the pattern of miniaturisation and the response to anti-androgen therapy is less consistent. The randomised trial that failed to show benefit in postmenopausal women is consistent with the hypothesis that DHT reduction is less central to FPHL than to male AGA. Women with elevated androgens due to conditions such as polycystic ovary syndrome may respond differently.

Alternatives for women with hair loss

The evidence-based treatment options for women include: topical minoxidil 2% or 5% foam (FDA-approved), oral minoxidil (off-label, see our oral minoxidil for women guide), and spironolactone (off-label, anti-androgen). For most women, topical minoxidil is the recommended starting point as the only FDA-approved drug for this indication.

Evidence at a glance

Study	Patients	Key finding
Mella 2010: oral finasteride systematic review	Multiple RCTs (predominantly men)	Finasteride effective in men. Evidence in women weak and mixed. Large RCT in postmenopausal women found no significant benefit vs placebo.

What the research cannot tell you

Whether a subset of women (e.g. those with elevated androgens) respond meaningfully to finasteride.
The optimal dose for off-label postmenopausal use if further trials are conducted.
The long-term safety profile of finasteride in women, including effects on bone density and cardiovascular health.
How finasteride compares to spironolactone in women with female pattern hair loss in a head-to-head trial.